Introduction
To treat cancer effectively, therapies must be developed to prevent the recurrence or metastatic spread of the disease. Previous studies have described the use of a variety of cytokines to induce antitumor immune responses with varying results. [1] [2] [3] [4] Using an ex vivo approach of tumor cell transduction, it was shown that many cytokines could modulate tumorigenicity and protect the host from untreated tumor cells. 1 Although potentially efficacious, an ex vivo approach using autologous tumor cell vaccination would require tumor cells from each patient to be removed, transduced and readministered presumably after inactivation by (for example) gamma-irradiation. A simpler and potentially more economical approach to the treatment of cancer is the administration and expression of cytokine genes locally at an established tumor site. In addition to eliminating the requirement for ex vivo manipulation of tumor cells, this approach might avoid the toxic side-effects that have been observed following the systemic administration of certain cytokines such as recombinant interleukin-2 (IL-2) and IL-12. 5, 6 We and others have previously demonstrated the ability of adenoviral (Ad) vectors expressing cytokines such as IL-2, IL-4 and IL-12 to modulate tumorigenicity and induce regression of established tumors following intratumoral vector delivery. [7] [8] [9] [10] [11] [12] Ad vectors rarely integrate into the host cell chromosome, thus transgene expression remains transient, a feature which may also be advantageous in cancer immunotherapy, as prolonged expression of immunostimulatory cytokines could lead to the induction of autoimmunity or other pathologies. 13, 14 The ability of various cytokines to induce antitumor immunity has been well documented and we have found in our model system that Ad vector-mediated delivery of IL-2 and IL-12 in particular was extremely effective in inducing regression of established tumors. 8, 12 The antitumor activity of IL-2 and IL-12 has been shown to be mediated through their ability to induce the cytotoxic activity of lymphokine-activated killer (LAK) cells, cyto-toxic T-lymphocytes (CTLs) and tumor infiltrating lymphocytes (TILs). [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] We and others have demonstrated that intratumoral injection of Ad vectors expressing IL-2 was effective in inducing potent antitumor immune responses leading to regression of established tumors in murine models of carcinoma. [8] [9] [10] This approach, however, was also associated with severe toxicities resulting in mortality in a large percentage of animals. 10 Side-effects have been reported in animal models following administration of therapeutic doses of systemic IL-12 and some toxicities were noted in a phase II clinical trial. 6, [25] [26] [27] In our studies, intratumoral administration of the AdIL-2 vector was associated with significant toxicity at levels required to induce complete tumor regression (this paper). Although no toxicities were observed following treatment with AdmIL-12.1, tumor recurrence was observed in approximately 50% of the animals whose tumors initially regressed. 12 There is precedent for IL-2 and IL-12 having synergistic effects in inducing many immunological functions, such as the induction of IFN-␥ expression, the activation of LAK cell cytolytic activity and the induction of antigen-specific CTL activity. [28] [29] [30] Furthermore, it has been shown that systemic administration of recombinant IL-2 protein enhanced the antitumor activity following administration of IL-12-transduced tumor cells. 31 Similarly, administration of recombinant IL-12 together with IL-2-transduced tumor cells was more efficacious than administration of transduced tumor cells alone. 32 Therefore, we examined the effectiveness of using lower doses of IL-2 in combination with IL-12 in an attempt to increase efficacy while simultaneously reducing toxicity of the treatment regimen.
The data presented here demonstrate that tumor regression following intratumoral administration of Ad vectors expressing IL-2 or IL-12 is associated with the induction of tumor antigen-specific CTL activity. Moreover, we demonstrate that the intratumoral coinjection of AdIL-2 and AdIL-12 is associated with increased frequency of regression of both primary and untreated distal tumors, and a reduction in the incidence of treatmentassociated mortality and tumor recurrence compared with treatment with either vector alone.
Results
Enhanced tumor regression following intratumoral coinjection of AdCAIL-2 and AdmIL-12.1 Previous studies using the polyoma middle T antigen transgenic model of mammary adenocarcinoma showed that Ad vectors expressing IL-2 or IL-12 were effective in mediating the regression of established tumors. 8, 12 In those studies, it was shown that intratumoral injection of 5 × 10 8 p.f.u. of AdCAIL-2 or AdmIL-12.1 could induce complete regression of tumors in 30-40% of treated animals. Although intratumoral injection with either AdCAIL-2 or AdmIL-12.1 was shown to mediate regression of distal untreated tumors, treatment with AdCAIL-2 was associated with lethal side-effects in a significant proportion of animals when used at doses required to induce tumor regression (32% mortality on average over eight separate experiments). There were no obvious toxicities associated with intratumoral injection of 1 × 10 8 p.f.u. of AdCAIL-2, however tumor regression was not elicited at this dose (data not shown). There were no toxic side-effects following AdmIL-12.1 administration; however, although greater than 70% of animals underwent initial tumor regression, only 30% of tumors regressed completely, with the remainder regrowing until the animals became moribund. 12 Since these two cytokines are known to act synergistically to induce expression of IFN-␥ and more potent CTL, LAK and NK cell activities, we decided to test the ability of a combination of IL-2 and IL-12-expressing Ad vectors to induce complete regression of tumors at doses of IL-2 that were less toxic. Tumor-bearing animals were injected intratumorally with either 5 × 10 8 p.f.u. of AdCAIL-2 or AdmIL-12.1 or a combination of 2.5 × 10 8 p.f.u. of each of AdCAIL-2 and AdmIL-12.1. It was found that injection of the combination of IL-2 and IL-12-expressing Ad vectors induced regression in 56% of treated animals, while injection of AdCAIL-2 or AdmIL-12.1 alone, resulted in complete tumor regression in about one-third of treated animals (Table 1) . A ⌾ 2 analysis indicated that the frequency of complete responses in animals treated with the combination of IL-2 and IL-12 was significantly different from that in animals treated with AdIL-2 or AdIL-12 alone (P = 0.0123 and 0.0044, respectively). Furthermore, there was a 6.5-fold increase in the therapeutic index (percentage of animals undergoing complete regression/percentage mortality) following administration of the combination of 2.5 × 10 8 p.f.u. of AdCAIL-2 and AdmIL-12.1 compared with 5 × 10 8 p.f.u. of AdCAIL-2 alone (10% lethality compared with 36%, respectively). Histological analysis of tissue from animals that had succumbed to toxicity indicated that for both the AdCAIL-2 and the AdCAIL-2+AdmIL-12.1 treatment groups, there were no apparent lesions in the lung, small intestine or the kidney. There were however, lesions in the liver and spleen of affected animals from both groups. Spleens were atrophied in the perivascular cuffs with marked necrosis of lymphocytes. In the liver, there was acute hepatitis, with marked infiltration of lymphocytes in perivascular regions, as well as some hepatic necrosis. The lesions in both treatment groups were similar in appearance, and were consistent with hepatocellular necrosis caused by Ad infection of the liver. This is probably a result of vector dissemination from the tumor and infection of distal organs.
Not only did injection of the combination of AdCAIL-2 and AdmIL-12.1 result in a decrease in the incidence of treatment-related mortality (as compared with that observed using the higher dose of AdCAIL-2 alone), the combination treatment was not associated with tumor recurrence following initial tumor regression as was seen for a number of animals following intratumoral injection of AdmIL-12.1 alone. These data suggest that the use of IL-2 in combination with IL-12 results in increased efficacy compared with administration of AdCAIL-2 or AdmIL-12.1 alone, and reduced incidence of mortality compared with intratumoral injection of AdCAIL-2 alone.
The antitumor activity of IL-2 has been shown to generate a Gaussian profile with respect to the dose administered, ie high concentrations of IL-2 secreted by transfected tumor cells resulted in an impaired stimulation of CTL activity. 33 To determine whether the increased antitumor activity observed following the intratumoral injection of the combination of AdCAIL-2 and AdmIL-12.1 was due to synergy resulting from expression of both a Mortality refers to the number of animals that succumbed to presumed IL-2-related toxicity between 6 to 10 days after adenoviral vector injection. The percentages reported in this column were calculated as the number of animals dying within 10 days divided by the total number of animals treated. b Complete refers to animals that have undergone total and permanent regression of the injected tumor; Partial refers to animals that have undergone partial tumor regression followed by regrowth, or a significant delay in growth; and None refers to animals whose tumors have continued to grow at a rate comparable to controls. Animals dying within 10 days after virus injection were excluded from the data tabulated in the response columns.
cytokines as opposed to increased potency resulting from reduced levels of expression of a single cytokine (ie 2.5 × 10 8 p.f.u. compared with 5 × 10 8 p.f.u. of vectors), a second set of experiments was carried out in which animals received 2.5 × 10 8 p.f.u. of cytokine vector (AdCAIL-2 or AdmIL-12.1) together with 2.5 × 10 8 p.f.u. of Addl70-3 (an E1 deleted control vector) for a total of 5 × 10 8 p.f.u. of vector, or received a combination of 2.5 × 10 8 p.f.u. of each of AdCAIL-2 plus AdmIL-12.1. Of the animals that received the combination of IL-2 plus IL-12, 64% underwent complete tumor regression, while in animals that received AdCAIL-2 plus Addl70-3, or AdmIL-12.1 plus Addl70-3, only 14 or 40%, respectively, of treated tumors completely regressed (Table 2 ). There was a statistically significant difference in the response rates for mice treated with AdIL-2 versus AdIL-2 and AdIL-12 (P = 0.0068). These results indicate that the increased incidence of tumor regression observed following administration of the combination of AdCAIL-2 and AdmIL-12.1 was probably a result of the synergistic effects of IL-2 and IL-12, as opposed to increased efficacy due to expression of a single cytokine at a reduced level.
Antitumor CTL activity induced by Ad vectors expressing IL-2 and IL-12
In our previous studies we observed that animals which had undergone tumor regression were also protected a Mortality refers to deaths due to presumed IL-2-related toxicity as in Table 1 . b Responses tabulated as in Table 1 .
from a subsequent tumor challenge on the opposite flank, indicating that a form of systemic immunity had been elicited. 8, 12 Since tumor therapies using IL-2 and IL-12 are associated with the activation of CTL in responding animals, 18, 26 we assayed for the presence of tumor antigenspecific CTL in the spleens of tumor-bearing and tumorfree animals using a nontumor-derived cell line (516MT3) which stably expressed the polyoma middle T antigen (PyMidT) as a CTL target in standard 51 Cr release assays. Splenocytes from mice whose tumors regressed following either AdCAIL-2 or AdmIL-12.1 treatment alone or in combination, displayed a high degree of 516MT3 target cell killing, but very little killing of the PyMidT negative target cell line PT0516 (Figure 1b, c and d, respectively) . In contrast, tumor-bearing animals that had been injected intratumorally with the Addl70-3 control vector exhibited no PyMidT-specific killing (Figure 1a ). Tumor-specific lysis was inhibited by the addition of anti-CD3 antibodies to the assay, indicating that the observed cytotoxic activity was mediated mainly by T-lymphocytes. Table 3 summarizes the results of analysis of CTL activity in tumor-free versus tumor-bearing animals following treatment with intratumoral injection of AdCAIL-2 or AdmIL-12.1. The CTL activity detected was graded based on the percent lysis of target cells at an effector to target ratio of 30:1 and the degree of killing in tumorfree animals was compared with that in tumor-bearing animals by 2 analysis. In general, for all three treatments, animals that had undergone tumor regression had significantly higher levels (P Ͻ 0.001) of specific CTL lysis (greater than 40%, at an effector to target ratio (E:T) of 30:1), while animals in which tumors persisted tended to have lower or no detectable CTL lysis levels (less than 40% at an E:T of 30:1). Thus tumor regression was found to correlate with the presence of tumor antigen-specific CTL isolated from the spleens of responding animals, suggesting that circulating anti-tumor immunity had been induced.
Tumor antigen-reactive lymphocytes secrete elevated levels of IFN-␥ Lymphocytes that had been cocultured with irradiated 516MT3 cells for 5 days, were restimulated in a fresh coculture with irradiated 516MT3 or PT0516 cells and 24 h later, the supernatants were analyzed by ELISA for the level of IFN-␥ expressed by the lymphocytes. The stimulation index was calculated as the ratio of IFN-␥ produced following stimulation with 516MT3 cells over that produced following stimulation with PT0516 cells (ie antigen-stimulation versus no antigen-stimulation). There was a striking difference in the secretion of IFN-␥ by lymphocytes isolated from animals which had undergone tumor regression compared with lymphocytes from tumor-bearing animals. Enhanced secretion of IFN-␥ was observed for animals that had been treated with AdCAIL-2 (15.0 ± 10.3 for tumor-free compared with 1.4 ± 1.2 for tumor-bearing animals) or with the combination of AdCAIL-2 and AdmIL-12.1 (11.0 ± 4.8 for tumor-free compared with 1.3 ± 0.9 for tumor-bearing animals). The results obtained from animals that had been treated with AdmIL-12.1 alone however, did not show the same enhancement in IFN-␥ expression (5.0 ± 4.5 for tumor-free compared with 1.3 ± 0.9 for tumor-bearing animals). In general, these results indicate that tumor regression associated with intratumoral injection of Ad vectors expressing IL-2 alone or in combination with IL-12 generates antigen-specific reactive T cells that express T1-type cytokines, which may be important for induction of tumor regression.
Intratumoral injection of AdCAIL-2 or AdmIL-12.1 can mediate regression of distal untreated tumors The detection of tumor antigen-specific CTLs in the spleens of animals responding to AdCAIL-2 and AdmIL-12.1 treatment suggested that there should also be circul- (Table 4 ). An additional 23% of AdCAIL-2-treated, and 39% of AdmIL-12.1-treated animals underwent complete regression of injected tumors but only partial antitumor responses in the untreated contralateral tumors. Thus in a significant proportion of treated animals, an antitumor response was elicited against the uninjected tumor, indicating that this treatment was able to induce systemic immunity that could induce regression of distal tumors. 'Mortality' refers to the number of animals that succumbed to presumed IL-2-related toxicity between 6 to 10 days after adenoviral vector injections. These animals were excluded from the data tabulated in responses.
AdCAIL-2+AdmIL-12.1, a significant reduction in tumor volume was observed (P Ͻ 0.0001) compared with control vector-treated tumors. The tumor volume of distal untreated tumors following all three treatments was also found to be significantly reduced compared with control vector treated animals, with P values of 0.0133, 0.0002, and Ͻ0.0001 for AdCAIL-2, AdmIL-12.1 and AdCAIL2+AdmIL-12.1 treated animals, respectively. Treatment with the combination of AdIL-2 and AdIL-12 was more effective in mediating regression of distal untreated tumors than AdIL-2 alone, with a P value of 0.0037 following ANOVA analysis of tumor volumes at day 19 after injection. Although the volumes of distal tumors at day 19 following treatment with AdCAIL-2 and AdmIL-12.1 were not statistically different from those obtained following treatment with AdmIL-12.1 alone (P = 0.1152), many animals in the group treated with AdmIL-12.1 alone succumbed to tumor recurrence and regrowth at later times, while animals treated with the combination of AdCAIL-2 and AdmIL-12.1 remained tumor free (greater than 12 months after vector injection). The data in Table 4 also indicate that intratumoral injection of the combination of AdCAIL-2 and AdmIL-12.1 was significantly more effective in inducing regression of both bilateral tumors compared with treatment with either AdCAIL-2 or AdmIL-12.1 alone (63% compared with 18 and 22%, respectively, ⌾ 2 P = 0.007 and 0.0193, respectively). These results indicate that intratumoral injection of Ad vectors expressing IL-2 and IL-12 was extremely effective in mediating regression of distal untreated tumors and may thus be effective in preventing the metastatic spread of the disease. 
Discussion
The use of adenoviral vectors to deliver foreign genes in vivo is ideal for cancer immunotherapy particularly of solid tumors. Ad vectors have been shown to infect and direct transgene expression in a wide variety of cell types, including epithelial, muscle, endothelial, neuronal and stromal cells. 34 One of the major disadvantages of Ad vectors for other gene therapy applications, namely the antiviral immune responses associated with their in vivo administration, 35 may not be detrimental in cancer immunotherapy and indeed may act as a form of adjuvant therapy that aids in the induction of a potent antitumor response. Ad vectors have been shown to infect cells in vivo with a high transduction efficiency, with a large proportion of the inoculated vector being maintained locally at the site of injection. 34 The transient nature of transgene expression from Ad vectors in vivo may also be an advantage when used in the context of cancer immunotherapy, as long-term overexpression of certain cytokines could lead to anergy or autoimmune disorders. 13, 14, 36 The cloning capacity of current first generation Ad vectors is 8 kb of foreign DNA, 37 which is more than sufficient for insertion of cytokine cDNAs identified to date, and even allows for the insertion of multiple cytokine genes within the same vector if desired. Furthermore, the use of mul-tiple Ad vectors expressing cytokine genes, facilitates the study of immunotherapeutic vectors in a variety of different combinations in vivo. These features make Ad vectors attractive for cancer immunotherapy approaches, and indeed, we and others have had considerable success using direct injection of Ad vectors expressing cytokines to modulate tumor growth in vivo. [8] [9] [10] [11] [12] We have previously demonstrated the ability of Ad vectors expressing IL-2 or IL-12 to mediate regression of established tumors following in vivo injection. 8, 11, 12 In the case of AdIL-2 vector injection, life-threatening toxicities were observed in a large percentage of animals (on average about 30%). Toloza et al 10 observed AdIL-2-related side-effects similar to those seen in our experiments, with the liver of treated animals exhibiting necrotic lesions that would severely impair normal liver function. This phenotype is probably a result of dissemination of the initial vector inoculum to sites other than the tumor, where expression of IL-2 could lead to activation and proliferation of antiviral CTLs and destruction of virally infected cells. It was also reported that following intratumoral injection of an Ad reporter vector, approximately 30% of the vector infected other systemic organ sites, indicating that dissemination of the virus inoculum had occurred. 10 Similar results showing the dissemination of virus inoculum following intratumoral injection have been obtained in our laboratory. 38 Intratumoral injection of an Ad vector expressing luciferase resulted in significant levels of luciferase expression in the spleen and liver of treated animals, however, this expression was greatly reduced if animals were pre-immunized against wildtype adenovirus. 38 Furthermore, pre-immunization resulted in only a three-fold decrease in transgene expression in the tumor (compared with a greater than 100-fold decrease in the liver), indicating that this type of approach might be adopted to decrease the toxicity induced by inappropriate expression of Ad-cytokine vectors in tissues other than tumors.
As a second approach to develop a therapy with greater efficacy than IL-2 or IL-12 alone and a reduced incidence of morbidity than that which is associated with the IL-2 therapy, in this study we examined the ability of AdCAIL-2 used in combination with AdmIL-12.1 to induce regression of established tumors. IL-2 and IL-12 are known to synergize in the induction of IFN-␥ expression, and induction of CTL, NK and LAK cell activity.
28-30 Although we did not compare the relative cytotoxic activity of CTLs (ie whether the antigen-specific CTL were more efficient at target killing, or whether there were increased numbers of antigen-specific CTL) isolated from animals that had undergone tumor regression following IL-2 plus IL-12 combination therapy, with those from animals receiving IL-2 or IL-12 alone, in all three treatment regimens we did detect tumor antigenspecific CTL activity that was inhibited by anti-CD3 antibodies (Figure 1 ). There may well be an increase in the cytotoxic activity of CTL, NK or LAK cells in IL-2 plus IL-12 treated animals compared with animals treated with either cytokine alone since it has been shown that lymphocytes isolated from the regional draining lymph nodes of lung cancer patients had increased proliferation, cytotoxic activity and expression of T1-type cytokines (such as IFN-␥) following incubation with both IL-2 and IL-12 compared with incubation with either cytokine alone. 39 The ability of IL-2 to synergize with IL-12 in the induction of IFN-␥ expression is a second possible mechanism to explain the increased tumor regression observed in the combination treatment. Elevated levels of IFN-␥, together with IL-12 will lead to the expression of T1-type cytokines and thus the induction of potent cell-mediated immune responses. 40 Lymphocytes isolated from animals that had undergone tumor regression were found to secrete elevated levels of IFN-␥ upon antigen stimulation, suggesting that indeed a type 1 profile was induced. Increased IFN-␥ expression has also been shown to increase the expression of MHC class I and class II molecules on tumor cells, 41 which would potentially render them more susceptible to T cell-mediated killing. IFN-␥ is also known to be a potent upregulator of the chemokines IP-10 (interferon inducible protein 10) and MIG (monokine induced by gamma interferon). 42, 43 Both of these molecules have been shown to be angiostatic [44] [45] [46] and thus increasing their expression would create a tumor microenvironment that is angiostatic resulting in inhibition of tumor growth.
The data described in this report indicate that the use of IL-2 and IL-12 together resulted in a statistically significant increase in the number of animals that respond by undergoing permanent tumor regression, accompanied by a decrease in mortality compared with that observed with higher doses of IL-2 vector alone. This enhanced efficacy was probably a result of synergistic actions of IL-2 and IL-12, as opposed to a biphasic dose effect, since using equivalent doses of the individual cytokines did not produce the same incidence of tumor regression seen with the combination vector treatment. Furthermore, we have demonstrated here that intratumoral injection of Ad-cytokine-expressing vectors can mediate regression of distal established untreated tumors. This may be a result of the ability to induce circulating tumor antigen-specific CTLs, or the cytokines themselves or immunomodulatory proteins such as IFN-␥ induced by the cytokines may also circulate from the site of vector injection to the distal tumor. We have previously demonstrated a highly localized expression of IL-12 following intratumoral injection with AdmIL-12.1, 12 but low levels of the cytokine can also be detected in the serum which could possibly modulate distal tumor regression.
Although in our polyoma middle T mammary adenocarcinoma model, the tumor cells express a potentially immunogenic tumor antigen, 100% of immunocompetent animals injected with 10 6 cells succumb to tumors and spontaneous regression is never seen, indicating that immune evasion mechanisms exist within these tumors. Our data indicate that potent antitumor immunity that can overcome these mechanisms can be induced following intratumoral injection of Ad vectors expressing cytokines. More importantly, this antitumor activity has the ability to migrate to, and elicit antitumor effects on distal untreated tumors. This is one of the first reports that intratumoral injection of Ad vectors expressing IL-2 or IL-12 can mediate regression of distal untreated tumors. Induction of specific antitumor immunity that can circulate and recognize distal tumors is of the utmost importance for establishing cancer therapy regimens that can protect patients from recurrent disease or metastases. Our results indicate that direct injection of Ad-cytokine vectors intratumorally can elicit such responses in our model of mammary adenocarcinoma, and support the further testing of these treatments in the clinic.
Materials and methods

Adenoviral vectors
The construction and characterization of all vectors used in these experiments have been described previously. 8, 37, 47 The vector AdCAIL-2 contains the cDNA for human IL-2 under the control of the human cytomegalovirus immediate-early promoter (HCMV) and the simian virus 40 (SV40) polyadenylation sequences in an E1-replacement, E3-deleted adenovirus type 5 (Ad5) vector backbone. 8 The AdmIL-12.1 vector contains the cDNA of each subunit of IL-12 protein (p35 and p40) under the control of the HCMV promoter and SV40 polyadenylation sequences, with the p35 expression cassette replacing E1 and the p40 expression cassette replacing E3 of Ad5. 47 The Addl70-3 vector is a control vector deleted for the E1 sequences and has a partial deletion/insertion mutation of the E3 region. 37 All viruses were propagated in 293 cells 48 which contain nucleotides 1 to 4344 of the wild-type Ad5 genome 49 and express the E1 proteins required for replication of E1-deleted vectors. Viruses for animal experimentation were purified on cesium chloride gradients as described. 50 
Animal model
The tumor model used in this study is based on a transgenic mouse model of mammary adenocarcinoma induced by expression of the polyoma middle T antigen (PyMidT) under control of the mouse mammary tumor virus long terminal repeat. 51 Typically, female transgenic mice develop spontaneous adenocarcinoma of all mammary epithelium by 8-10 weeks of age. These tumors were explanted and injected as single cell suspensions subcutaneously (s.c.) in the flanks of syngeneic immunocompetent animals where they formed tumors by 15-21 days after injection. 8, 11, 12 Tumors were injected intratumorally using an insulin syringe with the appropriate concentration of virus in a volume of 50 l. For contralateral experiments, animals were injected simultaneously in each flank with 10 6 explanted PyMidT tumor cells, and approximately 20 days later, when palpable tumors had formed, animals were injected in the right hind flank tumor with 5 × 10 8 p.f.u. of either AdCAIL-2, AdmIL-12.1 or Addl70-3 or a mixture of 2.5 × 10 8 p.f.u. of each of AdCAIL-2 and AdmIL-12.1. Tumors were measured in three dimensions using calipers and tumor volume was calculated assuming a prolate spheroid, as described previously. 8 
CTL assays
The mouse model used in these studies is based on the FVB/N strain which has an MHC haplotype of H2q. To generate a syngeneic cell line which could act as a PyMidT-specific CTL target, we established a permanent cell line from the kidneys of 5-day-old baby FVB/N mice. This cell line (PT0516) was then cotransfected with a plasmid carrying a neo resistance marker (pSV2neo) and one carrying the PyMidT gene under control of the Moloney murine leukemia virus long terminal repeat (pJ4⍀MT). G418 resistant cell clones were isolated and PyMidTexpressing lines were identified by Western blot analysis using a PyMidT-specific monoclonal antibody 52 (C152, gift of B Griffin, Royal Postgraduate Medical School, London, UK). The cell clones were tested for their potential as CTL targets by the ability to be lysed by PyMidT-specific CTLs isolated from the popliteal lymph nodes of animals immunized via footpad injection with an Ad vector expressing PyMidT. 53 One PyMidT positive cell line that was efficiently lysed by CTLs, 516MT3, was selected for use in all subsequent CTL assays.
For CTL assays by 51 Cr release, spleens were removed and minced through mesh screens, the red blood cells lysed by incubation in 0.83% ammonium chloride and the lymphocytes set up in coculture with irradiated (50 Gy) 516MT3 cells at a ratio of 100:1 for a period of 5 days. Following coculture, standard 51 Cr release assays were carried out in 96-well V-bottomed microtiter plates essentially as described 54 using 516MT3 (PyMidT-expressing) or PT0516 (negative for PyMidT expression) as CTL target cell lines. After 6 h of incubation at 37°C, supernatants were removed and the released 51 Cr counted in a gamma counter. Abrogation of T-lymphocyte mediated cell lysis by anti-CD3 antibody was tested by the addition of 3 l per well of an anti-CD3 ascitic fluid (145-2C1166, gift of K Croitoru, McMaster University, Hamilton, Ontario Canada).
IFN-␥ ELISAs
A portion of each lymphocyte coculture used in the CTL assay was once again cocultured with irradiated (50 Gy) 516MT3 or PT0516 cells in a V-bottomed 96-well microtiter plate (effector to simulator ratio of 30:1) for a further 24 h. The amount of IFN-␥ present in the coculture supernatants was determined by ELISA as described previously, 12 in flat-bottomed 96-well microtiter plates (Nunc Maxisorp, Burlington, Ont, Canada) which had been coated at 4°C overnight with 10 g/ml rabbit polyclonal anti-IFN-␥ serum (gift of S Kunkel, University of Michigan, Ann Arbor, MI, USA). Following blocking with 2% bovine serum albumin in phosphate-buffered saline for 90 min at 37°C, the supernatants were either added to the wells neat or at a 1:2 dilution. The bound IFN-␥ was detected by addition of 4 g/ml biotinylated rabbit polyclonal anti-IFN-␥ serum, followed by addition of avidin-conjugated horseradish peroxidase (BioRad, Mississauga, Ont, Canada) and chromogenic development using the OPD peroxidase substrate (Pierce, Brockville, Ont, Canada). The reaction was terminated by the addition of 3 n H 2 SO 4 , and the amount of IFN-␥ present was quantified following absorbance readings at 490 nm by interpolation of a standard curve generated by known amounts of recombinant IFN-␥, using the DeltaSoft II program.
